Adam Kupinski

Adam Kupinski is a highly experienced scientist currently serving as Principal Scientist I at both AbbVie and DJS Antibodies since 2022 and 2021, respectively. Prior to these roles, Adam held multiple positions at Ipsen Bioinnovation from 2016 to 2021, ultimately advancing to Senior Scientist in Protein Sciences. Adam's earlier career included a visiting scientist position and postdoctoral research at the University of Leeds, focusing on aberrant recombination events and their link to cancer. Additional postdoctoral experience at the Center for Regenerative Therapies Dresden involved analyzing the Hedgehog signaling pathway, while work at the Max Planck Institute revolved around Ste20 kinases in germ line development. Adam completed a PhD in Biology at the International Max Planck Research School and holds a Master of Science in Biotechnology from the University of Gdańsk.